Stay updated with breaking news from Nasdaq Cmpx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,190,000 shares, an increase of 5.3% from the April 15th total of 2,080,000 shares. Based on an average daily trading volume, of 364,900 shares, the days-to-cover ratio […]
Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last […]
Compass Therapeutics (NASDAQ:CMPX – Get Rating) and BioAtla (NASDAQ:BCAB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Valuation & Earnings This table compares Compass Therapeutics and BioAtla’s […]
Compass Therapeutics (NASDAQ:CMPX – Get Rating) and Valneva (NASDAQ:VALN – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations. Institutional and Insider Ownership 54.3% of Compass Therapeutics shares are […]
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 2,130,000 shares, an increase of 17.7% from the February 28th total of 1,810,000 shares. Based on an average daily trading volume, of 376,700 shares, the days-to-cover ratio is currently 5.7 […]